Literature DB >> 3260852

In vitro activity of cefotaxime against clinically significant pathogens.

S Nakashio1, M Nakamura.   

Abstract

The present in vitro antibacterial activities of cefotaxime and 8 other cephalosporins (cefoperazone, cefmenoxime, cefpiramide, latamoxef, cefamandole, cefmetazole, cefotiam and cephazolin) were evaluated simultaneously in 384 strains of Gram-positive cocci, 595 strains of Enterobacteriaceae, 240 strains of non-fermenters and 143 strains of anaerobes and miscellaneous organisms. The results were expressed as minimum inhibitory concentration (MIC) range, MIC50 and MIC90. Of the beta-lactams, cefotaxime and latamoxef exhibited the highest activity against a wide variety of Gram-positive and Gram-negative bacteria. MIC90 of cefotaxime, however, for species of Pseudomonas aeruginosa, Xanthomonas maltophilia, enterococci, Bacteroides sp. and Clostridium difficile were more than 100 mg/L. Cefpiramide and cefoperazone were generally less active than these 2 agents. All strains were tested for beta-lactamase production by the cefinase disc method and the relationship of susceptibility to beta-lactams was evaluated in each species. The need was demonstrated for periodic susceptibility testing to be performed to better guide empirical antimicrobial therapy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3260852     DOI: 10.2165/00003495-198800352-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  12 in total

1.  [Serotype and antibiotic susceptibility of Staphylococcus aureus and Pseudomonas aeruginosa isolated from burn patients, with special reference to hospital infection].

Authors:  S Nakashio; I Kikugawa; M Nakamura; I Harasawa; C Yanagawa; Y Tanaka; K Ashikawa; N Maeda
Journal:  Kansenshogaku Zasshi       Date:  1986-03

2.  Chromogenic cephalosporin spot test to detect beta-lactamase in clinically significant bacteria.

Authors:  K Montgomery; L Raymundo; W L Drew
Journal:  J Clin Microbiol       Date:  1979-02       Impact factor: 5.948

Review 3.  Beta-lactam antibiotics.

Authors:  G N Rolinson
Journal:  J Antimicrob Chemother       Date:  1986-01       Impact factor: 5.790

4.  Antibacterial activity of cefotaxime.

Authors:  S Mitsuhashi; M Inoue; S Masuyoshi
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

5.  Antibacterial activity of cefotaxime and other newer cephalosporins (in vitro and in vivo).

Authors:  E Schrinner; M Limbert; L Penasse; A Lutz
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

6.  Comparative in vitro activity of moxalactam, cefotaxime, cefoperazone, piperacillin, and aminoglycosides against gram-negative bacilli.

Authors:  T O Kurtz; D J Winston; J A Hindler; L S Young; W L Hewitt; W J Martin
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

7.  Comparison of cefoperazone, cefotaxime, and moxalactam (LY127935) against aerobic gram-negative bacilli.

Authors:  S D Lang; D J Edwards; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

8.  Safety of cefotaxime and other new beta-lactam antibiotics.

Authors:  R H Parker; S Park
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

9.  Characterization of anaerobic gram-negative bacilli by using rapid slide tests for beta-lactamase production.

Authors:  A M Bourgault; J E Rosenblatt
Journal:  J Clin Microbiol       Date:  1979-06       Impact factor: 5.948

10.  [The antibacterial activity of new cephem antibiotics against clinical isolates. A comparison of the antibacterial activity of cefotaxime with 6 other antibiotics].

Authors:  T Miwatani; Y Takeda; K Kotera; T Nishimura; T Takashima; K Hiromatsu; K Tabuki; S Fujimoto; T Kamiki; E Yoshizaki; E Yabuuchi; Y Shimizu; K Matsunaga; K Yamanaka; I Furuta; M Iimori; J Kodama; M Tanaka; K Maejima; M Nukina; E Takashima; M Takahashi; O Harikane; T Masutani
Journal:  Jpn J Antibiot       Date:  1983-02
View more
  1 in total

1.  No Outbreak of Vancomycin and Linezolid Resistance in Staphylococcal Pneumonia over a 10-Year Period.

Authors:  Josef Yayan; Beniam Ghebremedhin; Kurt Rasche
Journal:  PLoS One       Date:  2015-09-23       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.